Breaking News Instant updates and real-time market news.

ISRG

Intuitive Surgical

$709.44

-5.47 (-0.77%)

, TRXC

TransEnterix

$1.85

-0.0099 (-0.53%)

14:08
10/18/16
10/18
14:08
10/18/16
14:08

On The Fly: What to watch in Intuitive Surgical earnings report

Intuitive Surgical (ISRG) is scheduled to report results of its third fiscal quarter after the market close on October 18, with a conference call scheduled for 4:30 pm EDT. What to watch for: 1. PROCEDURAL GROWTH: Along with its second quarter report, Intuitive Surgical raised its much watched procedural growth view for its daVinci system to 14%-15% from 12%-14%. On July 20, the day after Intuitive Surgical's second quarter report, research firm Stifel increased its price target on Intuitive Surgical after the company's products carried out more procedures than expected in Q2 and its financial results beat expectations. The firm said at the time it thinks that the company's procedure growth and gross margin guidance could prove conservative even after they were increased on the Q2 earnings call. The firm said that the company's pipeline is gaining momentum, and it kept a Buy rating on the shares. 2. COMPETITOR PROBLEMS. On April 20, another robotic surgery company, TransEnterix (TRXC), which industry experts viewed as a growing competitive threat to Intuitive Surgical, announced that the FDA determined the company's SurgiBot System does not meet the criteria for substantial equivalence based upon the data and information submitted by TransEnterix in its 510(k) submission. "The FDA's decision is extremely disappointing. We are in the process of reviewing all aspects of the FDA's communication," said Todd Pope, president and CEO of TransEnterix. A day later on April 21, Piper Jaffray analyst Matt O'Brien concluded that TransEnterix's announcement that the FDA had rejected the 510 submission for its SurgiBot robotic system as a incremental positive for Intuitive Surgical. The delay may impact both the ongoing European launch and the upcoming domestic introduction of TransEnterix's more feature-rich ALF-X product, O'Brien told investors in a research note. At the time, he said he believed TransEnterix is the biggest near-term competitive threat to Intuitive. O'Brien kept a Neutral rating on Intuitive Surgical due to valuation. 3. HERNIA OPPORTUNITY: During its earnings conference call last quarter, the company's chief executive officer Gary Guthart commented on the opportunity it sees in hernia repair: "Trends in U.S. general surgery growth continued with strong growth in inguinal hernia repair and ventral hernia repair followed by continued growth in colorectal surgery. Customer feedback and commitment to the use of daVinci in performing inguinal hernia repair for complex conditions has been encouraging in the quarter, increasing our confidence in its long-term acceptance." On September 19, Leerink analyst Richard Newitter said he left the Annual Global Symposium on Robotic-Assisted and Minimally Invasive Hernia Repair "incrementally more positive" on the adoption outlook for Intuitive Surgical's robotic hernia category. Hernia can remain a source of upside for the company's general surgery division, Newitter told investors in a research note. He reiterated an Outperform rating on the shares with a $780 price target.

ISRG

Intuitive Surgical

$709.44

-5.47 (-0.77%)

TRXC

TransEnterix

$1.85

-0.0099 (-0.53%)

  • 18

    Oct

  • 29

    Nov

ISRG Intuitive Surgical
$709.44

-5.47 (-0.77%)

09/15/16
SBSH
09/15/16
NO CHANGE
SBSH
Buy
New prostate study a positive for Intuitive Surgical, says Citi
Citi analyst Amit Hazan noted that a new study published in the New England Journal of Medicine found no difference in mortality between prostrate cancer patients treated with surgery or radiation and those placed on active monitoring after 10 years. However, men assigned to active monitoring were significantly more likely to have metastatic disease, Hazan highlighted, calling the study a positive for Intuitive Surgical, as it may help doctors "swing the pendulum" back to treatment. The analyst, who thinks Intuitive's da Vinci Prostatectomy procedures can grow above incidence rates for several years, keeps a Buy rating on the stock.
09/19/16
LEER
09/19/16
NO CHANGE
Target $780
LEER
Outperform
Leerink positive on Intuitive Surgical's hernia opportunity
Leerink analyst Richard Newitter says he left this weekend's Annual Global Symposium on Robotic-Assisted and Minimally Invasive Hernia Repair "incrementally more positive" on the adoption outlook for Intuitive Surgical's robotic hernia category. Hernia can remain a source of upside for the company's gen surgery division, Newitter tells investors in a research note. He reiterates an Outperform rating on the shares with a $780 price target.
09/20/16
SBSH
09/20/16
NO CHANGE
Target $779
SBSH
Buy
Intuitive Surgical procedure upside looks likely, says Citi
Following his firm's semi-annual urology survey and gynecology survey, Citi analyst Amit Hazan believes more procedure upside for Intuitive Surgical looks likely. The results point to continued strength in Intuitive's legacy categories that make up nearly 70% of its U.S. procedures, Hazan tells investors in a research note. He keeps a Buy rating on the shares with a $779 price target.
10/13/16
WELS
10/13/16
INITIATION
WELS
Outperform
Intuitive Surgical initiated with an Outperform at Wells Fargo
Wells Fargo analyst Larry Biegelsen started Intuitive Surgical with an Outperform rating and $815-$825 price target range. The analyst expects continued adoption of hernia repair and colorectal procedures to drive "strong growth" in the United States and views the company's international opportunity as underappreciated. Biegelsen sees "several reasons" for why Intuitive's share outperformance to continue.
TRXC TransEnterix
$1.85

-0.0099 (-0.53%)

04/21/16
PIPR
04/21/16
NO CHANGE
PIPR
Neutral
TransEnterix rejection a positive for Intuitive Surgical, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien views TransEnterix's (TRXC) announcement that the FDA had rejected the 510 submission for its SurgiBot robotic system as a incremental positive for Intuitive Surgical (ISRG). The delay may impact both the ongoing European launch and the upcoming domestic introduction of TransEnterix's more feature-rich ALF-X product, O'Brien tells investors in a research note. The analyst believes TransEnterix is the biggest near-term competitive threat to Intuitive. O'Brien keeps a Neutral rating on Intuitive Surgical due to valuation.
04/21/16
RBCM
04/21/16
NO CHANGE
RBCM
TransEnterix price target lowered to $4 from $6 at RBC Capital
RBC Capital cut its price target on TransEnterix after the FDA decided not to approve the company's application for its SurgiBot product. However, the firm thinks the company's ALF-X system could be successful, and it keeps an Outperform rating on the name.
05/11/16
LSCM
05/11/16
DOWNGRADE
Target $2
LSCM
Hold
TransEnterix downgraded to Hold from Buy at Lake Street
Lake Street analyst Bruce Jackson downgraded TransEnterix to Hold saying he prefers to wait on the sidelines until the SurgiBot issues are resolved. The analyst has a $2 price target for the shares.
10/07/16
RILY
10/07/16
INITIATION
Target $3
RILY
Buy
TransEnterix initiated with a Buy at B. Riley
B. Riley analyst Greg Chodaczek started TransEnterix with a Buy rating and $3 price target. The analyst sees a large market opportunity for robotic-assisted surgical systems.

TODAY'S FREE FLY STORIES

KBR

KBR

$14.05

-1.43 (-9.24%)

18:47
04/28/17
04/28
18:47
04/28/17
18:47
Hot Stocks
KBR issues statement on SFO investigation »

KBR made the following…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

SMMT

Summit Therapeutics

$11.00

-0.4 (-3.51%)

18:32
04/28/17
04/28
18:32
04/28/17
18:32
Hot Stocks
Summit Therapeutics publishes results from CoDIFy trial online »

Summit Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TKPYY

Takeda Pharmaceutical Co. Ltd.

$24.83

0.85 (3.54%)

18:14
04/28/17
04/28
18:14
04/28/17
18:14
Hot Stocks
Takeda says FDA grants accelerated approval of ALUNBRIG »

Takeda Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FNBC

First NBC Bank

$2.65

-0.2 (-7.02%)

18:07
04/28/17
04/28
18:07
04/28/17
18:07
Hot Stocks
FDIC named receiver of First NBC Bank »

First NBC Bank, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SGBK

Stonegate Bank

$45.90

-0.52 (-1.12%)

17:47
04/28/17
04/28
17:47
04/28/17
17:47
Earnings
Stonegate Bank reports Q1 non-GAAP EPS 56c, consensus 57c »

Reports Q1 NII $25.89M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PROV

Provident Financial

$19.23

-0.03 (-0.16%)

17:45
04/28/17
04/28
17:45
04/28/17
17:45
Hot Stocks
Provident Financial announces extension of stock repurchase plan »

Provident Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

YGE

Yingli Green Energy

$2.66

-0.03 (-1.12%)

17:40
04/28/17
04/28
17:40
04/28/17
17:40
Hot Stocks
Yingli Green Energy files extension for 2016 Form 20-F filing »

Yingli Green Energy has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EPC

Edgewell Personal Care

$71.49

-0.14 (-0.20%)

17:40
04/28/17
04/28
17:40
04/28/17
17:40
Hot Stocks
Breaking Hot Stocks news story on Edgewell Personal Care »

Gabelli raises stake in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

ORC

Orchid Island Capital

$10.60

-0.33 (-3.02%)

17:35
04/28/17
04/28
17:35
04/28/17
17:35
Syndicate
Breaking Syndicate news story on Orchid Island Capital »

Orchid Island Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 13

    Jun

AEP

American Electric

$67.83

-0.27 (-0.40%)

17:35
04/28/17
04/28
17:35
04/28/17
17:35
Hot Stocks
AEP Generation Resources seeks bids for supply of coal »

AEP Generation Resources,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORC

Orchid Island Capital

$10.60

-0.33 (-3.02%)

17:34
04/28/17
04/28
17:34
04/28/17
17:34
Syndicate
Breaking Syndicate news story on Orchid Island Capital »

Orchid Island Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 13

    Jun

HBHC

Hancock Holding

$46.70

-0.5 (-1.06%)

, FNBC

First NBC Bank

$2.65

-0.2 (-7.02%)

17:34
04/28/17
04/28
17:34
04/28/17
17:34
Hot Stocks
Whitney to acquire branches, assets, liabilities of First NBC from FDIC »

Hancock Holding Company…

HBHC

Hancock Holding

$46.70

-0.5 (-1.06%)

FNBC

First NBC Bank

$2.65

-0.2 (-7.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

TSLA

Tesla

$314.07

5.44 (1.76%)

17:31
04/28/17
04/28
17:31
04/28/17
17:31
Periodicals
Tesla aims to hire engineers from Mexico to work at CA plant, Reuters says »

Tesla is aiming to hire…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 30

    May

LMT

Lockheed Martin

$269.45

-1.69 (-0.62%)

17:22
04/28/17
04/28
17:22
04/28/17
17:22
Hot Stocks
Lockheed Martin awarded $332.1M government contract »

Lockheed Martin, Orlando,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

BA

Boeing

$184.83

1.61 (0.88%)

17:21
04/28/17
04/28
17:21
04/28/17
17:21
Hot Stocks
Boeing awarded $541M government contract modification »

The Boeing Co., Ridley…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

WBA

Walgreens Boots Alliance

$86.54

0.65 (0.76%)

, RAD

Rite Aid

$4.00

0.05 (1.27%)

17:20
04/28/17
04/28
17:20
04/28/17
17:20
Periodicals
Walgreens to push regulators over decision on Rite Aid deal, NY Post says »

Walgreens (WBA) will…

WBA

Walgreens Boots Alliance

$86.54

0.65 (0.76%)

RAD

Rite Aid

$4.00

0.05 (1.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$28.99

-0.09 (-0.31%)

17:20
04/28/17
04/28
17:20
04/28/17
17:20
Hot Stocks
General Electric awarded $670.7M government contract »

General Electric, Lynn,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

  • 31

    May

  • 22

    Jun

SIX

Six Flags

$62.61

-0.26 (-0.41%)

17:19
04/28/17
04/28
17:19
04/28/17
17:19
Hot Stocks
Six Flags in agreement to repurchase 5M shares from HP Partners »

Six Flags Entertainment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 17

    May

  • 18

    May

LMT

Lockheed Martin

$269.45

-1.69 (-0.62%)

17:18
04/28/17
04/28
17:18
04/28/17
17:18
Hot Stocks
Lockheed Martin awarded $1.38B government contract »

Lockheed Martin Corp.,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

SBBP

Strongbridge Biopharma

$4.50

0.05 (1.12%)

17:16
04/28/17
04/28
17:16
04/28/17
17:16
Syndicate
Breaking Syndicate news story on Strongbridge Biopharma »

Strongbridge Biopharma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    May

CYH

Community Health

$8.61

0.18 (2.14%)

17:12
04/28/17
04/28
17:12
04/28/17
17:12
Hot Stocks
Community Health completes divestiture of Anniston, Alabama hospital »

Community Health…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 03

    May

  • 06

    Jun

MRUS

Merus

$22.20

-0.14 (-0.63%)

17:07
04/28/17
04/28
17:07
04/28/17
17:07
Earnings
Merus reports Q4 EPS (EUR1.91) vs. (EUR0.77) last year »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Jun

  • 06

    Jun

AEZS

Aeterna Zentaris

$3.35

0.3 (9.84%)

17:01
04/28/17
04/28
17:01
04/28/17
17:01
Hot Stocks
Aeterna Zentaris to announces top-line Zoptrex phase 3 results on Monday »

Aeterna Zentaris will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

ANY

Sphere 3D

$0.19

-0.006 (-3.13%)

17:00
04/28/17
04/28
17:00
04/28/17
17:00
Syndicate
Breaking Syndicate news story on Sphere 3D »

Sphere 3D files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    May

MRUS

Merus

$22.20

-0.14 (-0.63%)

16:56
04/28/17
04/28
16:56
04/28/17
16:56
Hot Stocks
Merus provides anticipated 2017 pipeline milestones »

Merus provided 2017…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Jun

  • 06

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.